Teamwork Financial Advisors LLC Sells 9,787 Shares of Natera, Inc. $NTRA

Key Points

• Teamwork Financial Advisors cut its Natera stake by 90.5%, selling 9,787 shares and retaining 1,028 shares worth approximately $425,000. Institutional investors collectively own 99.90% of Natera.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above analyst expectations, while its loss of $0.47 per share was slightly better than forecast.
• Analysts remain broadly bullish, with a consensus rating of “Moderate Buy” and an average price target of $374.64; several firms recently raised their targets, including Canaccord Genuity to $500.

Teamwork Financial Advisors LLC trimmed its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 90.5% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,028 shares of the medical research company's stock after selling 9,787 shares during the quarter. Teamwork Financial Advisors LLC's holdings in Natera were worth $425,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Natera during the second quarter valued at about $2,962,770,000. Arrowstreet Capital Limited Partnership lifted its stake in Natera by 1.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company's stock valued at $238,334,000 after buying an additional 11,793 shares during the period. Maverick Capital Ltd. grew its holdings in Natera by 24.1% during the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company's stock valued at $234,315,000 after purchasing an additional 227,605 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Natera by 10.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company's stock valued at $226,220,000 after buying an additional 80,440 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in Natera in the 2nd quarter valued at $199,960,000. Institutional investors own 99.90% of the company's stock.

Insider Buying and Selling

In related news, CFO Michael Brophy sold 2,419 shares of the firm's stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $253.96, for a total value of $614,329.24. Following the transaction, the chief financial officer owned 54,295 shares in the company, valued at approximately $13,788,758.20. This trade represents a 4.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 6,517 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the completion of the transaction, the insider directly owned 197,257 shares of the company's stock, valued at approximately $63,424,043.21. This trade represents a 3.20% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 52,985 shares of company stock worth $16,119,137 over the last three months. Company insiders own 5.05% of the company's stock.

Natera Stock Performance

Shares of NASDAQ NTRA traded up $5.98 during midday trading on Monday, reaching $399.42. The company's stock had a trading volume of 1,328,970 shares, compared to its average volume of 1,401,286. The company has a market cap of $57.57 billion, a P/E ratio of -293.69 and a beta of 1.50. The business's 50 day moving average price is $358.21 and its two-hundred day moving average price is $275.88. Natera, Inc. has a fifty-two week low of $181.00 and a fifty-two week high of $437.41.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm's quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.74) earnings per share. Sell-side analysts forecast that Natera, Inc. will post -1.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Canaccord Genuity Group raised their price objective on shares of Natera from $375.00 to $500.00 and gave the stock a "buy" rating in a research report on Monday. UBS Group increased their price objective on Natera from $290.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, September 9th. BTIG Research lifted their target price on Natera from $290.00 to $320.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Royal Bank Of Canada boosted their target price on shares of Natera from $350.00 to $460.00 and gave the company an "outperform" rating in a research report on Friday, September 25th. Finally, Evercore restated an "outperform" rating and issued a $300.00 price target on shares of Natera in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $374.64.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.